secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001104659-26-036445
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)
--------------------------------------------------------------------------------

- TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.
- Nebulized Tyvaso significantly reduced risk of clinical worsening; benefits seen across all subgroups.
- Integrated analyses of TETON-1 and TETON-2 show statistically significant treatment effects on primary and most secondary endpoints.
- Plan to submit sNDA to FDA by summer 2026 for priority review to add IPF indication for Tyvaso.
- Safety profile consistent with prior Tyvaso studies; no new safety signals observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926036445/0001104659-26-036445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465926036445/tm2610558d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-036445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer